Recombinant human haptoglobin beta subunit expression and purification method and application of recombinant human haptoglobin beta subunit in rhabdomyolysis-related acute kidney injury
Through the method of codon optimization and GST tag binding, the expression difficulties of recombinant human taxoglobin β subunit in the prokaryotic cell expression system were solved, and the highly expressed and purified protein was obtained, and it was shown in acute renal injury related to rhabdomyolysis. Output treatment effect.
Patent Information
- Application Number
- CN202310510373.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-05-08
- Publication Date
- 2024-11-08
AI Technical Summary
In the prior art, the expression level of recombinant human haptoglobin β subunit in the prokaryotic cell expression system is low, and the Hp proteins sold on the market are mainly derived from precious human plasma, and are not easy to obtain and invest in large quantities.
Through codon optimization technology, the human β-subunit gene was inserted into the prokaryotic expression vector pGEX-6P-1 and expressed in E. coli BL21 (DE3), and purified in combination with GST tags to obtain highly efficient expression and purification of recombinant humans. Hiroglobin beta subunit protein.
The efficient expression and purification of the recombinant human haptoglobin β subunit protein was achieved, providing proteins for in vitro experiments, and showing therapeutic potential in rhabdomyolysis-related acute renal injury.
Smart Images

Figure CN118910067A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the technical field of gene engineering, and specifically relates to a method for expressing and purifying a recombinant human haptoglobin β subunit and an application thereof in acute kidney injury associated with rhabdomyolysis. Background Art
[0002] Acute kidney injury (AKI) is an important complication of rhabdomyolysis (RM). When skeletal muscle cells are destroyed due to squeezing, ischemia, etc., some cell contents such as myoglobin (Mb) and potassium ions enter the blood circulation. This then causes a clinical syndrome characterized by myoglobinemia, myoglobinuria, hyperkalemia, metabolic acidosis, acute kidney injury, and even multiple organ dysfunction. About 10-60% of RM patients suffer from acute kidney injury due to hypermyoglobinemia. Currently, there is no targeted drug that is truly effective in treating rhabdomyolysis-related acute kidney injury (RM-AKI), and the prognosis of patients is poor.
[0003] Haptoglobin (Hp) belongs to a family of acute phase plasma proteins that are synthesized almost exclusively in the liver and are rapidly upregulated in response to stress. Hp genes are rapidly, significantly, and persistently expressed in the renal cortex during RM-AKI and may affect the pathogenesis and / or outcome of acute kidney injury through antioxidative and inflammatory responses. Severe injury can lead to Hp protein depletion, which can compromise the health of the body. In addition, Hp was originally discovered as the most important plasma detoxifier of hemoglobin. An intravenous formulation of Hp protein derived from human blood has been approved for marketing in Japan for the treatment of hemoglobinemia and hemoglobinuria associated with hemolysis. Given the structural homology between Mb and the α subunit of hemoglobin, it is speculated that the binding site of the α subunit of hemoglobin, the haptoglobin β subunit (Hpβ) protein, can specifically bind to Mb. However, whether Hpβ protein can play a potential therapeutic role by interacting with injury-related factors during acute kidney injury remains to be further explored. In addition, the main source of Hp protein sold on the market is precious human plasma, which is not easy to obtain in large quantities and invest in research.
[0004] The invention patent with application publication number CN110724185A discloses a method for expressing and purifying a recombinant human haptoglobin β subunit protein. The method for expressing a recombinant human haptoglobin β subunit protein comprises the following steps: firstly, inserting a human haptoglobin β subunit gene into a prokaryotic expression vector pET32a(+), constructing a recombinant expression vector pET32a(+)-HPβ, and transforming the above recombinant expression vector into Escherichia coli ShuffleT7-B to obtain a recombinant human haptoglobin β subunit engineering strain, culturing the above engineering strain and then adding IPTG to induce the expression of the recombinant human haptoglobin β subunit. However, the prokaryotic expression of the recombinant human Hpβ gene is greatly affected by codon preference. The codon adaptation index (CAI) of the Hpβ gene in the Escherichia coli host is low, and the protein expression level is low. Summary of the invention
[0005] The purpose of the present invention is to provide a recombinant human haptoglobin β subunit gene, which is codon-optimized and has a GST tag, so that recombinant human haptoglobin β subunit protein can be simply and quickly prepared, and the obtained recombinant human haptoglobin β subunit protein can be directly used in in vitro GST pulldown experiments, has a wide range of applications, and is helpful to further study the ability of human haptoglobin β subunit protein to bind to and clear serum myoglobin.
[0006] The second object of the present invention is to provide a method for expressing and purifying recombinant human haptoglobin β subunit, thereby optimizing the expression level of human haptoglobin β subunit protein.
[0007] The third object of the present invention is to provide a use of recombinant human haptoglobin in the drug treatment of rhabdomyolysis-related acute kidney injury.
[0008] In order to achieve the above objectives, the technical solution adopted by the present invention is: a recombinant human haptoglobin β subunit gene, the nucleotide sequence of the recombinant human haptoglobin β subunit gene is shown in SEQ ID NO.1.
[0009] A method for expressing and purifying a recombinant human haptoglobin β subunit as described above comprises the following steps: optimizing the nucleotide sequence of a human haptoglobin β subunit gene fragment based on the codon preference of a host cell expression system, inserting the optimized human haptoglobin β subunit gene into a prokaryotic expression vector pGEX-6P-1, constructing a recombinant expression vector pGEX-6P-1-Hpβ, transforming pGEX-6P-1-Hpβ into a host cell competent cell C, obtaining a recombinant human haptoglobin β subunit engineering strain C-pGEX-6P-1-Hpβ, culturing C-pGEX-6P-1-Hpβ, and then adding IPTG to induce the expression of recombinant human GST-Hpβ protein inclusion bodies; and purifying the obtained recombinant human GST-Hpβ protein inclusion bodies.
[0010] Furthermore, the method for constructing the recombinant expression vector includes the following steps: naming the optimized human haptoglobin β subunit gene as the OPT-Hpβ gene; designing PCR primers, wherein the forward primer sequence is 5'-CCGGAATTCCGTATTCTGGGTGGTCATC-3', and the reverse primer sequence is 5'-GTGCTCGAGTTAATTTTCTGCAATGGTTTTC-3; using the PCR primers to perform PCR amplification on the OPT-Hpβ gene, performing double enzyme digestion treatment on the amplified product of the OPT-Hpβ gene with EoRI / XhoI, and recovering the gene fragment containing the OPT-Hpβ gene after double enzyme digestion; performing double enzyme digestion treatment on the prokaryotic expression vector pGEX-6P-1 with EcoRI and XhoI, and then recovering the vector fragment containing the prokaryotic expression vector pGEX-6P-1 after double enzyme digestion; performing a ligation reaction on the recovered vector fragment and the gene fragment, and then transforming them into competent cells C to obtain the engineering strain pGEX-6P-1-Hpβ.
[0011] Furthermore, the culture method of C-pGEX-6P-1-Hpβ includes the following steps: picking a single colony of the engineered strain C-pGEX-6P-1-Hpβ and inoculating it into LB culture medium, and culturing it on a shaker overnight; inoculating the overnight cultured C-pGEX-6P-1-Hpβ culture liquid into LB culture medium, culturing until the OD600 of the C-pGEX-6P-1-Hpβ culture liquid reaches 0.4 to 0.6, and adding IPTG to induce the expression of recombinant human GST-Hpβ protein inclusion bodies.
[0012] Furthermore, the purification of the recombinant human GST-Hpβ protein inclusion bodies includes the following steps: inducing the expression of recombinant human GST-Hpβ protein inclusion bodies, centrifuging the culture medium after the induction expression is completed, collecting the lower layer bacterial precipitate, re-selecting the bacteria, breaking the bacteria in an ice bath by ultrasonication, washing the bacterial precipitate with a human GST-Hpβ protein inclusion body washing buffer after centrifugation, and denaturing and dissolving the bacterial precipitate with a human GST-Hpβ protein inclusion body dissolution buffer; dialyzing the denatured solution containing the recombinant human GST-Hpβ protein inclusion bodies with a dialysis buffer; loading the renatured solution containing the recombinant human GST-Hpβ protein inclusion bodies onto a GST-tagged protein agarose purification column, washing the purification column with 15 times the column volume of the washing buffer, and then eluting with the elution buffer, collecting the eluate, concentrating the eluate with a 10KDa ultrafiltration tube and replacing it with a PBS solution.
[0013] Furthermore, the host cell competent cell C includes but is not limited to Escherichia coli BL21 (DE3) and ShuffleT7-B.
[0014] The use of recombinant human haptoglobin obtained by the above method in the drug treatment of rhabdomyolysis-related acute kidney injury.
[0015] Beneficial effects of the present invention:
[0016] Aiming at the difficulty of expressing recombinant human haptoglobin β subunit in a prokaryotic cell expression system, the present invention adopts codon optimization technology to construct a cell line that can be efficiently expressed in a prokaryotic cell expression system, thereby providing a guarantee for the yield of haptoglobin β subunit protein.
[0017] The present invention constructs a prokaryotic expression vector of a recombinant human haptoglobin β subunit with a GST tag, and obtains an engineered bacterium expressing the recombinant protein by transforming the Escherichia coli BL21 (DE3) strain, thereby obtaining the expression of the recombinant protein. The purified recombinant human haptoglobin β subunit protein can be directly used in an in vitro GST pulldown experiment.
[0018] The present invention provides a method for constructing a prokaryotic expression vector of a human haptoglobin β gene with high protein yield and simple operation, which can simply and quickly prepare recombinant human haptoglobin β subunit protein, avoid the problem of human plasma, and compound the corresponding buffer system and purification strategy, thereby providing technical guarantee for the yield, purity and activity of human haptoglobin β subunit protein.
[0019] The recombinant human haptoglobin β subunit protein with a GST tag in the present invention can specifically bind to myoglobin and exert a therapeutic effect on mice with acute kidney injury associated with rhabdomyolysis. In addition, the recombinant human haptoglobin β subunit protein may also exert a potential therapeutic effect by interacting with other injury-related factors during acute kidney injury. BRIEF DESCRIPTION OF THE DRAWINGS
[0020] Figure 1 It is a schematic diagram of the nucleotide sequence comparison between the WT-Hpβ gene and the OPT-Hpβ gene of the present invention;
[0021] Figure 2 This is an identification diagram of the successfully constructed pGEX-6P-1-Hpβ plasmid of the present invention after double digestion with EcoRI and XhoI endonucleases;
[0022] Figure 3 The sequence diagram (part) of the pGEX-6P-1-Hpβ plasmid of the present invention;
[0023] Figure 4 This is a Coomassie brilliant blue staining image of the BL21(DE3)-pGEX-6P-1-Hpβ engineering strain of the present invention for inducing expression of recombinant human haptoglobin β subunit protein;
[0024] Figure 5 This is a Coomassie brilliant blue staining diagram of the purification result of the recombinant human haptoglobin β subunit protein of the present invention;
[0025] Figure 6 This is a protein immunoblot image of the purification result of the recombinant human haptoglobin β subunit protein of the present invention;
[0026] Figure 7 This is a mass spectrometry comparison diagram of the purification results of the recombinant human haptoglobin β subunit protein of the present invention;
[0027] Figure 8 This is a protein immunoblot image of the pull-down results of the recombinant human haptoglobin β subunit protein and mouse myoglobin GST of the present invention;
[0028] Fig. 9 The present invention shows the effect of the recombinant human haptoglobin β subunit protein on the renal function of CS-AKI mice. DETAILED DESCRIPTION
[0029] The present invention will be further described below in conjunction with the embodiments of the present invention and the accompanying drawings.
[0030] Example 1
[0031] The method for expressing and purifying the recombinant human haptoglobin β subunit of this embodiment comprises the following steps:
[0032] 1. Codon Optimization
[0033] The human haptoglobin β subunit gene fragment was optimized based on the codon preference of the Escherichia coli expression system, and the ratio of guanine to cytosine, codon adaptation index, optimal codon usage frequency, mRNA secondary structure and restriction site avoidance were comprehensively evaluated. The optimized sequence was named OPT-Hpβ, and the comparison results with the unoptimized sequence (WT-Hpβ) are shown in Figure 2. Figure 1 WT-Hpβ is 738 bp in length and encodes 245 amino acids. The gene sequence is shown in SEQ ID NO.3. This optimization involves the adjustment of 140 amino acid codons, with a similarity of 78.86% to the original sequence. In the optimization, some scarce codons were replaced with favorable codons based on the preference of Escherichia coli, and the adaptation index of the target gene in the host cell was increased from 0.74 to 0.95, which is beneficial to the efficiency of positively regulating the translation of mRNA into protein.
[0034] 2. Construction of recombinant expression vector
[0035] 1) Design PCR primers and use them to amplify the OPT-Hpβ gene; clone the OPT-Hpβ gene containing a stop codon, add an EcoRI recognition site to the 5' end, and add an XhoI recognition site to the 3' end; the primer sequences are as follows: forward primer sequence F: 5'-CCG GAATTC CGTATTCTGGGTGGTCATC-3', the underline is the EcoRI restriction site; reverse primer sequence R: 5'-GTG CTCGAG TTAATTTTCTGCAATGGTTTTC-3', the underline is the XhoI restriction site; the amplified product of the OPT-Hpβ gene is obtained, the amplified product of the OPT-Hpβ gene is double-digested with EoRI / XhoI, and the gene fragment containing the OPT-Hpβ gene after double digestion is recovered.
[0036] 2) The prokaryotic expression vector pGEX-6P-1 was double-digested with EcoRI and XhoI, and then the vector fragment containing the prokaryotic expression vector pGEX-6P-1 after double-digestion was recovered. pGEX-6P-1 contains Tac promoter and protein purification GST tag sequence.
[0037] 3) The recovered vector fragment and the gene fragment were ligated with T4 DNA ligase, transformed into DH5α competent cells, and cloned and cultured. After selecting a single colony for PCR verification, culture, plasmid extraction, double enzyme digestion and sequencing verification, the engineered bacteria pGEX-6P-1-Hpβ were obtained. The results are as follows Figure 2 and Figure 3 As shown, Figure 2In the figure, lane M: DNAMarker; lane 1: pGEX-6P-1-Hpβ after double digestion with EcoRI and XhoI restriction endonucleases; the size of pGEX-6P-1 plasmid is 4969 bp, the size of synthetic gene is 747 bp, and the fragment size is in line with expectations. Figure 3 In the figure, the white area is the full-length Hpβ gene sequence, and the gray area is the sequence on the vector. Figure 3 The sequencing results showed that the HPβ subunit gene fragment was correctly inserted into the plasmid.
[0038] 3. Expression and verification of recombinant human haptoglobin β subunit protein
[0039] 1) The correctly sequenced pGEX-6P-1-Hpβ plasmid was transformed into E. coli BL21(DE3) competent cells to obtain the recombinant human haptoglobin β subunit engineering strain BL21(DE3)-pGEX-6P-1-Hpβ. Pick a single colony of the recombinant human haptoglobin β subunit engineering strain BL21(DE3)-pGEX-6P-1-Hpβ, inoculate it into 10mL LB medium, and culture it overnight at 37°C and 200rpm on a shaking incubator. The LB medium also contains 100μg / mL of ampicillin.
[0040] 2) Inoculate the overnight cultured BL21(DE3)-pGEX-6P-1-Hpβ into 200 mL LB medium at a ratio of 1:10, and culture at 37°C and 200 rpm for 2 h until the OD600 of the BL21(DE3)-pGEX-6P-1-Hpβ culture reaches 0.6. Then, add IPTG at a final concentration of 0.2 mM to induce expression for 4 h to induce the expression of recombinant human GST-Hpβ protein inclusion bodies.
[0041] After the induction of expression, PBS buffer was added to the culture medium, and after ultrasonic disruption, the culture medium was centrifuged at 4°C, 8000 rpm for 10 min, and the supernatant and precipitate were collected and tested by SDS-PAGE electrophoresis and Coomassie brilliant blue staining. Figure 4 As shown, wherein lane M: protein Marker; KDa: protein molecular weight; lane 1: pGEX-6P-1-Hpβ strain precipitation component is not induced; lane 2: pGEX-6P-1-Hpβ strain supernatant component is not induced; lane 3: pGEX-6P-1-Hpβ strain precipitation component is induced with 0.2mM IPTG; lane 4: pGEX-6P-1-Hpβ strain supernatant component is induced with 0.2mM IPTG. Figure 4 It showed that after induction with IPTG, the protein at 55KDa increased significantly.
[0042] The nucleotide sequence of the recombinant human haptoglobin β subunit gene of this example is shown in SEQ ID NO.1, and the amino acid sequence is shown in SEQ ID NO.2.
[0043] 4. Purification of recombinant human haptoglobin β subunit protein
[0044] 1) Induce recombinant human GST-Hpβ protein inclusion bodies. After the induction expression is completed, the culture medium is centrifuged at 4°C, 8000rpm for 10 minutes to collect the lower bacterial precipitate. Reselect the bacteria at a ratio of PBS buffer: bacterial precipitate = 10mL: 1g. Ultrasonic disruption of the bacteria in an ice bath, centrifugation, washing the bacterial precipitate 2 to 3 times with a recombinant human GST-Hpβ protein inclusion body washing buffer containing 50mMTris, 150mMNaCl, 2mMEDTA, 1mMDTT, 2MUrea, pH8.0, and then using a recombinant human GST-Hpβ protein inclusion body dissolution buffer containing 10mMTris, 100mMNaH2PO4, 8MUrea, pH8.0 overnight to denature and dissolve the bacterial precipitate.
[0045] 2) The denatured solution containing the recombinant human GST-Hpβ protein inclusion bodies was dialyzed with dialysis buffer for renaturation. The dialysis bag size was 8-14KDa, the temperature was 4°C, the time was 12 h, and the dialysis buffers were 50mM Tris, 150mM NaCl, 2mM EDTA, 5% glycerol, 6MUrea, pH8.0; 50mM Tris, 150mM NaCl, 2mM EDTA, 5% glycerol, 4MUrea, pH8.0; 50mM Tris, 150mM NaCl, 2mM EDTA, 5% glycerol, 2MUrea, pH8.0; PBS, pH8.0, and the dialysis buffer was replaced every 2 h.
[0046] 3) The renatured solution containing the recombinant human GST-Hpβ protein inclusion body was loaded onto the GST-tagged protein agarose purification column, and the purification column was washed with 15 column volumes of a washing buffer containing 10mM Na2HPO4, 1.8mM KH2PO4, 140mM NaCl, 2.7mM KCl, pH 7.4, and then eluted with an elution buffer containing 50mMTris, 10mM GSH, pH 8.0, and the eluate was collected, concentrated with a 10KDa ultrafiltration tube and replaced with a PBS solution. The results were detected by Coomassie Brilliant Blue staining and protein immunoblotting, and verified by mass spectrometry. Figure 5 , Figure 6 and Figure 7 shown. Figure 5 Middle lane M: protein marker; KDa: protein molecular weight; Lane 1: purified GST-tagged protein; Lane 2: purified recombinant human haptoglobin β subunit protein. Figure 6 Middle lane M: protein marker; KDa: protein molecular weight; Lane 1: purified recombinant human haptoglobin β subunit protein. Figure 7 The mass spectrometry identification results of recombinant human haptoglobin β subunit protein show that the molecular weight of the purified recombinant human haptoglobin β subunit protein is about 55KDa, which is consistent with the expected molecular weight; the mass spectrometry matching peptide is A0A0C4DGL8·A0A0C4DGL8_HUMAN (UniProt).
[0047] Example 2
[0048] The interaction between the recombinant human haptoglobin β subunit protein and myoglobin in this example:
[0049] GST-pulldown assay was used to verify the interaction between recombinant human haptoglobin β subunit and myoglobin:
[0050] 1. The purified recombinant human haptoglobin β subunit protein was incubated with muscle lysates from CS-AKI mice at 4°C for 0.5 h for binding, and then incubated with agarose resin at 4°C overnight.
[0051] 2. After washing twice with PBS, add 1xSDS-PAGE loading buffer, heat at 100℃ for 5min, and detect by Western blot analysis. The results are as follows Figure 8 shown.
[0052] Depend on Figure 8 It can be seen that the recombinant human haptoglobin β subunit protein can interact with myoglobin.
[0053] Example 3
[0054] The recombinant human haptoglobin β subunit protein of this example improves the renal function of RM-AKI mice:
[0055] 1. Construction of RM-AKI mouse model and drug administration regimen
[0056] Male C57BL / 6 mice (about 20 g, 8-10 weeks old) were housed in a pathogen-free environment at 22 ± 2 °C with a light and dark cycle and were acclimatized for 7 days before use in the experiment with free access to food. Male C57BL / 6 mice were randomly divided into 3 groups: normal group, injury group, and treatment group;
[0057] Normal group: no modeling and drug treatment;
[0058] Injury group: RM-AKI model was established, that is, after anesthetizing mice, 50% (w / v) glycerol was intramuscularly injected into the femoral muscles of the bilateral hind limbs of each mouse at a dose ratio of 8 mL / kg body weight, without drug treatment;
[0059] Treatment group: RM-AKI model was established. Immediately after successful modeling, 0.2 mL of recombinant human haptoglobin β subunit protein was intraperitoneally injected at a dose-body weight ratio of 40 mg / kg.
[0060] II. Recombinant human haptoglobin β subunit protein treatment improves renal function in RM-AKI mice
[0061] 24 hours after the release of the squeeze, the tGFR renal function real-time monitoring and intelligent analysis system (Mindikang TM ) Detection of glomerular filtration rate of male C57BL / 6 mice in each group:
[0062] 1. Connect the sensor and battery and fix the sensor on the shaved back skin of male C57BL / 6 mice in each group;
[0063] 2. After fixing the sensor, the tracer was intravenously injected into male C57BL / 6 mice in each group at a dose-body weight ratio of 7 mg / 100 g;
[0064] 3. The sensor device detected the fluorescence content in the shaved back skin of male C57BL / 6 mice in each group within 1.5 h;
[0065] 4. Data collection and software analysis, the results are as follows Fig. 9 shown.
[0066] Depend on Fig. 9 It can be seen that compared with the normal group, the glomerular filtration rate of male C57BL / 6 mice in the squeeze group decreased significantly, that is, the renal function was severely impaired. In the treatment group given recombinant human haptoglobin β subunit protein, the glomerular filtration rate of male C57BL / 6 mice increased significantly, indicating that recombinant human haptoglobin β subunit protein can significantly improve the renal function of male C57BL / 6 mice with CS-AKI.
Claims
1. A recombinant human haptoglobin β subunit gene, characterized in that: The nucleotide sequence of the recombinant human haptoglobin β subunit gene is shown in SEQ ID NO.
1.
2. A method for expressing and purifying a recombinant human haptoglobin β subunit according to claim 1, characterized in that: The method comprises the following steps: optimizing the nucleotide sequence of a human haptoglobin β subunit gene fragment based on the codon preference of a host cell expression system, inserting the optimized human haptoglobin β subunit gene into a prokaryotic expression vector pGEX-6P-1, constructing a recombinant expression vector pGEX-6P-1-Hpβ, transforming pGEX-6P-1-Hpβ into a host cell competent cell C, obtaining a recombinant human haptoglobin β subunit engineering strain C-pGEX-6P-1-Hpβ, culturing C-pGEX-6P-1-Hpβ, and then adding IPTG to induce the expression of recombinant human GST-Hpβ protein inclusion bodies; and purifying the obtained recombinant human GST-Hpβ protein inclusion bodies.
3. The method for expressing and purifying the recombinant human haptoglobin β subunit according to claim 2, characterized in that: The construction method of the recombinant expression vector comprises the following steps: naming the optimized human haptoglobin β subunit gene as the OPT-Hpβ gene; designing PCR primers, wherein the forward primer sequence is 5'-CCGGAATTCCGTATTCTGGGTGGTCATC-3', and the reverse primer sequence is 5'-GTGCTCGAGTTAATTTTCTGCAATGGTTTTC-3; using the PCR primers to perform PCR amplification on the OPT-Hpβ gene, performing double enzyme digestion treatment on the amplified product of the OPT-Hpβ gene with EoRI / XhoI, and recovering the gene fragment containing the OPT-Hpβ gene after double enzyme digestion; performing double enzyme digestion treatment on the prokaryotic expression vector pGEX-6P-1 with EcoRI and XhoI, and then recovering the vector fragment containing the prokaryotic expression vector pGEX-6P-1 after double enzyme digestion; performing a ligation reaction on the recovered vector fragment and the gene fragment, and then transforming a competent cell C to obtain an engineering strain pGEX-6P-1-Hpβ.
4. The method for expressing and purifying the recombinant human haptoglobin β subunit according to claim 2, characterized in that: The C-pGEX-6P-1-Hpβ culture method comprises the following steps: picking a single colony of the engineering strain C-pGEX-6P-1-Hpβ and inoculating it into an LB culture medium, and culturing it on a shaking table overnight; inoculating the overnight cultured C-pGEX-6P-1-Hpβ bacterial liquid into the LB culture medium, culturing until the OD600 of the C-pGEX-6P-1-Hpβ bacterial liquid reaches 0.4 to 0.6, and adding IPTG to induce the expression of recombinant human GST-Hpβ protein inclusion bodies.
5. The method for expressing and purifying recombinant human haptoglobin β subunit according to claim 2, characterized in that: The purification of the recombinant human GST-Hpβ protein inclusion body comprises the following steps: inducing the expression of the recombinant human GST-Hpβ protein inclusion body, centrifuging the culture fluid after the induction expression is completed, collecting the lower bacterial cell precipitate, resuspending the bacterial cells, breaking the bacterial cells by ultrasonication in an ice bath, washing the bacterial cell precipitate with a human GST-Hpβ protein inclusion body washing buffer after centrifugation, deforming and dissolving the bacterial cell precipitate with a human GST-Hpβ protein inclusion body dissolution buffer; dialyzing the denatured solution containing the recombinant human GST-Hpβ protein inclusion body with a dialysis buffer; loading the refolded solution containing the recombinant human GST-Hpβ protein inclusion body onto a GST-tagged protein agarose purification column, washing the purification column with 15 times the column volume of the washing buffer, eluting with an elution buffer, collecting the eluate, concentrating the eluate with a 10KDa ultrafiltration tube and replacing it with a PBS solution.
6. The method for expressing and purifying the recombinant human haptoglobin β subunit according to claim 2, characterized in that: The host cell competent cell C includes but is not limited to Escherichia coli BL21 (DE3) and ShuffleT7-B.
7. Use of the recombinant human haptoglobin obtained by the method according to claim 2 in drug treatment of acute kidney injury associated with rhabdomyolysis.
Citation Information
Cited By
FGF23 mutant and medicine for preventing or treating acute kidney injury
CN121471337A
